Lv11
30 积分 2026-01-21 加入
An advanced comprehensive muti-cell-type-specific model for predicting anti-PD-1 therapeutic effect in melanoma
49分钟前
已完结
Clinicopathological and molecular correlates of clinical benefit from disitamab vedotin (RC48), a HER-2-targeting antibody-drug conjugate, in metastatic urothelial carcinoma: a multi-center, real-world study
59分钟前
已完结
Natural killer cell infiltration elicits gender‐dependent dichotomous clinical outcomes in urothelial carcinoma
1小时前
已完结
Re: A Multicenter Randomized Phase II Trial of Lenvatinib plus Everolimus Versus Cabozantinib in Patients with Metastatic Clear Cell RCC that Progressed on PD-1 Immune Checkpoint Inhibition (LenCabo)
1小时前
已完结
皖公网安备34019202002308
